XML 63 R35.htm IDEA: XBRL DOCUMENT v3.25.4
Collaboration and Licensing Agreements (Tables)
 12 Months Ended
Dec. 31, 2025
Collaboration and Licensing Agreements [Abstract]  
Schedule of Revenue
Disaggregation of total revenues by nature is as follows:
Year Ended December 31,
(in thousands)202520242023
Product sales, net$377,808 $319,196 $82,526 
Product supply revenue15,879 11,649 6,121 
Licensing revenue5,088 78 35,809 
Non-cash royalty revenue related to the sale of future royalties8,545 2,692 — 
Total revenues$407,320 $333,615 $124,456 
Total product sales, net was as follows:
Year Ended December 31,
(in thousands)202520242023
Product sales, net
IBSRELA$274,207 $158,286 $80,062 
XPHOZAH103,601 160,910 2,464 
Total product sales, net$377,808 $319,196 $82,526 
Product sales, net as a percentage of total revenues
92.8 %95.7 %66.3 %
The following table summarizes total revenues by collaboration partner:
Year Ended December 31,
(in thousands)202520242023
Licensing revenue
Kyowa Kirin
$— $— $30,000 
Fosun Pharma
5,000 — 5,000 
METiS
— — 750 
Knight
88 78 59 
Total licensing revenue
$5,088 $78 $35,809 
Product supply revenue   
Kyowa Kirin
$15,625 $11,649 $6,092 
Knight
254 — 29 
Total supply revenue
$15,879 $11,649 $6,121 
Non-cash royalty revenue related to the sale of future royalties   
Kyowa Kirin
$8,545 $2,692 $— 
Schedule of Deferred Revenue Balances
The following table presents changes in our current and non-current deferred revenue balances, which are primarily attributable to Kyowa Kirin:
20252024
(in thousands)CurrentNon-CurrentCurrentNon-Current
Deferred revenue balance as of January 1,
$10,686$7,232$7,182$8,644
Prepaid product supply1,4336,4673,7168,212
Product supply delivered(10,913)—(9,836)—
Reclassify amounts to be recognized in the next twelve months——9,624(9,624)
Deferred revenue balance as of December 31,$1,206$13,699$10,686$7,232